Acute kidney injury as a possible immune-related adverse event associated with sustained complete response to BRAF and MEK inhibitors in advanced, V600E-mutated melanoma

The interesting work by Ben-Betzalel et  al. [1] highlighted the potential incidence of immune-related adverse events (irAEs), which are typically associated with immune-checkpoint inhibitors, among patients with melanoma treated with BRAF and MEK inhibitors. In fact, these tyrosine-kinase inhibitors (TKIs) exert several immunomodulating effects, mainly linked to increased tumour-released antigens, increased expression of major histocompatibility complex class I, increased recruitment of CD8+ T cells, inhibition of T regulatory cells and decreased programmed death ligand 1 (PD-L1) expression [2,3].
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research